Hepatitis E virus (HEV)
infection is now established as an emerging enteric viral hepatitis. Standard treatments
in acute and chronic hepatitis E remain to be established.
This study
undertakes a review of the epidemiology, treatment implication and vaccine
prevention from published literature. HEV infection is a worldwide public
health problem and can cause acute and chronic hepatitis E. HEV genotypes 1 and
2 are primarily found in developing countries due to waterborne transmission,
while the zoonotic potential of genotypes 3 and 4 affects mostly industrialized
countries. An awareness of HEV transmission through blood donation, especially
in the immunocompromised and solid organ transplant patients, merits an
effective anti-viral therapy.
There are currently no clear indications for the
treatment of acute hepatitis E. Despite concerns for side effects, ribavirin
monotherapy or in combination with pegylated interferon alpha for at least 3 mo
appeared to show significant efficacy in the treatment of chronic hepatitis E.
However, there are no available treatment options for specific patient
population groups, such as women who are pregnant. Vaccination and screening of
HEV in blood donors are currently a global priority in managing infection.
New
strategies for the treatment and control of hepatitis E are required for both
acute and chronic infections, such as prophylactic use of medications,
controlling large outbreaks, and finding acceptable antiviral therapy for
pregnant women and other patient groups for whom the current options of
treatment are not viable.
Full article at: http://goo.gl/4drquV
By:
Ga Young Lee,
Kittiyod Poovorawan, Department of Clinical Tropical Medicine, Faculty of
Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
Duangnapa
Intharasongkroh, Pattaratida Sa-nguanmoo, Sompong Vongpunsawad, Yong
Poovorawan, Center of Excellence in Clinical Virology, Department of Pediatrics,
Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
Duangnapa
Intharasongkroh, National Blood Centre, Thai Red Cross Society, Bangkok 10330,
Thailand
Chintana
Chirathaworn, Department of Microbiology, Faculty of Medicine, Chulalongkorn
University, Bangkok 10330, Thailand
Author contributions: Poovorawan Y designed and outlined the
research; Lee GY, Poovorawan K, Intharasongkroh D, Sa-nguanmoo P, Vongpunsawad
S and Chirathaworn C wrote the paper.
Correspondence to: Yong Poovorawan, MD, Professor, Center of
Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,
Chulalongkorn University, Rama IV Rd, Bangkok 10330, Thailand. ht.ca.aluhc@p.gnoy
Telephone: +66-2-2564909 Fax: +66-2-2564929
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment